1. Home
  2. CCB vs GERN Comparison

CCB vs GERN Comparison

Compare CCB & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coastal Financial Corporation

CCB

Coastal Financial Corporation

HOLD

Current Price

$50.01

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.56

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCB
GERN
Founded
1997
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
2018
1996

Fundamental Metrics

Financial Performance
Metric
CCB
GERN
Price
$50.01
$1.56
Analyst Decision
Strong Buy
Hold
Analyst Count
3
3
Target Price
$126.67
$2.17
AVG Volume (30 Days)
197.5K
9.2M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.85
EPS
N/A
N/A
Revenue
N/A
$1,065,000.00
Revenue This Year
$96.61
$26.91
Revenue Next Year
$22.66
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$36.61
$1.04
52 Week High
$120.05
$2.01

Technical Indicators

Market Signals
Indicator
CCB
GERN
Relative Strength Index (RSI) 43.90 51.20
Support Level $45.24 $1.46
Resistance Level $53.02 $1.64
Average True Range (ATR) 1.99 0.07
MACD 1.09 -0.01
Stochastic Oscillator 53.04 41.67

Price Performance

Historical Comparison
CCB
GERN

About CCB Coastal Financial Corporation

Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: